spacer
home > pmps > summer 2017 > reducing risks
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Reducing Risks

A pharmaceutical product’s ability to perform its purpose depends on its quality; the user expects the product to be safe, therapeutic and completely fit for function. To meet these criteria, it needs to be intrinsically stable, free of contamination and must reproducibly deliver the therapeutic benefit claimed on the label or in the product information leaflet to the consumer over the period of its shelf life. Such a product is said to deliver its quality through its design, hence the phrase ‘Quality by Design’ (QbD). QbD focuses on integrated product development, commencing at the concept stage (1). These principles have been adopted by the FDA for the discovery, development and manufacturing of drugs and have been developed further for biopharmaceutical products (2,3).

When a product is developed with raw material selection in mind, designing quality and removing formulationassociated risks are key considerations. To this end, using the best materials available is crucial to help manage these aspects of chemistry. Depending on how the drug is to be administered (topically, orally or parenterally), raw material choices and their attributes need to be deliberated, especially where key ‘natural’ materials are to be used. A control strategy needs to be developed for the entire process, including tight supervision on the excipients’ specifications, to ensure consistent quality and product stability over its shelf life.

As such, excipient selection plays a key role in determining the performance of a drug – not only in delivering the efficacy required, but also maintaining this over the product’s lifetime.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Anthony Hubbard, Research and Technology Manager in Health Care at Croda Europe, has worked in product development for over 30 years. He has been involved in the innovation, development and testing of a variety of healthcare, cosmetic and toiletry formulations. In his position at Croda, Anthony’s current focus is on the development of drug delivery systems (parenteral, oral and topical) that enhance the stability and availability of APIs. He has a Bachelor of Science (Hons) and is a fellow of the Royal Society of Chemistry.
spacer
Anthony Hubbard
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

TheVax Genetics Vaccine CO., Ltd and Biotechpharma UAB to collaborate on cGMP production of THEVAX HBV Vaccine

VILNIUS, Lithuania and TAIPEI, Taiwan, April 30, 2018 /PRNewswire/ -- TheVax Genetics Vaccine CO., Ltd (6567.TWO) and Biotechpharma UAB have entered into a manufacturing agreement to produce THEVAX HBV vaccine for first-in-human clinical trials.
More info >>

White Papers

Delivering Fit For Purpose Biomanufacturing CHO Cell Lines

Fujifilm Diosynth Biotechnologies

The challenge during mammalian cell line development is to identify and isolate stable, high expressing cell lines producing product with the appropriate critical product quality attributes rapidly, reproducibly and with relative ease. Obtaining a host cell line that inherently exhibits desirable biomanufacturing attributes can therefore have a significantly positive effect on the identification of recombinant cell lines with desired traits during cell line development screens. In this study, we demonstrate that it is possible to exploit intrinsic heterogeneity within host cell populations and identify host cell lines which are more “fit for purpose”.
More info >>

 
Industry Events

BioPharm America 2018

5-6 September 2018, Hynes Convention Center

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement